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Supplemental Figure 1. Expression pattern of CIP2A, MycN and cMyc mRNA 
during neural crest migration and in the trunk neural plate/tube. A) At stage HH9, 
expression of CIP2A is visible in the ectoderm and in the neural crest cells that are about 
to emigrate from the dorsal neural tube. MycN is expressed in the rest of the neural tube 
that will form the central nervous system, and is complementary to cMyc that is only 
expressed in the dorsal neural crest domain. B) At stage HH10, the expression patterns 
are similar to stage HH9, although very low levels of MycN expression is visible in the 
migrating neural crest cells. Pax7 marks the neural crest at premigratory stage, and 
HNK1 in the migrating cells. Similar to anterior regions, MycN and CIP2A expression is 
seen throughout the body from anterior to posterior in the trunk neural tube (black 
arrows) all the way to the neural plate in the lumbosacral region (white arrows). Similar 
to anterior regions, cMyc is not expressed before the premigratory neural crest stage in 
the more posterior parts of the embryo. Scale bar 20µm. 	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Supplemental Figure 2. Morpholinos specifically block translation of CIP2A and 
MycN, Sox2 is downregulated in MycN overexpressing cells after emigration. 
A) Illustration demonstrating the double sided gene expression perturbation technique 
for chick embryos. At gastrula stage (HH4), either morpholinos or DNA with two different 
fluorescent dyes are injected into contralateral sides of the embryo and targeted to the 
ectoderm using electroporation. The embryos, grown ex ovo on filter papers in albumin, 
are placed in 37oC until they reach the desired stage. B) To verify that the morpholino 
correctly binds to its target sequence, constructs with about 50bp covering the 5’ end / 
transcription start side region were cloned upstream of RFP coding sequence without 
ATG.  As the morpholino binds, no RFP will be translated. C) CIP2A morpholino and D) 
MycN morpholino efficiently block translation of RFP and thus bind to their respective 
specific target sites. E) Loss of neural crest phenotype induced by CIP2AMo is efficiently 
rescued by co-expression of CIP2A as shown by FoxD3 in situ hybridization. F) MycN 
expressing migrating neural crest cells downregulate their Sox2 expression after 
emigration, no Sox2-positive migrating cells are seen on either side of the embryo.  At 
early migration, the phenotype seen in the premigratory neural crest persists: fewer early 
neural crest cells emigrate from the MycN overexpressing side, and the dorsal neural 
crest domain is smaller as indicated by Pax7 staining (n=3).  Scale bar 20µm. 	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Supplemental Figure 3. Strong correlation between CIP2A, MycN and poor 
prognosis in SEQC498 data set while cMyc correlates with better survival 
probability.  A) Expression of cMyc and MycN show negative correlation in clinical 
neuroblastoma samples, B) whereas MycN correlates positively with CIP2A as shown 
both in the complete data set as well as in Stage 4 tumors. Presumably due to the 
extremely high expression levels, the correlation is weakest in the MycN amplified stage 
4 tumors. C) Expression of CIP2A correlates significantly according to INSS stage, and 
cMyc shows an inverse correlation. D) CIP2A and cMyc display a modest negative 
correlation in the complete data set but the correlation in this data set is lost in Stage 4 
tumors. E) Kaplan-Meier curve showing a significantly lower survival probability for 
patients with high CIP2A in the complete data set and in the MycN non-amplified tumors 
(with more “physiological MycN expression levels, see Fig 6B), and the correlation is lost 
in the Stage 4 tumors and the MycN amplified group (bonf p= 1). F) High cMyc 
expression levels (which may reflect rather physiological than overexpressed levels) 
correlate with better survival probability in clinical neuroblastoma both in the complete 
and Stage 4 data set, whereas G) MycN, as previously known, correlates with the poor 
outcome.  	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Supplemental Figure 4. Strong correlation between CIP2A, MycN and poor 
prognosis in Versteeg88 data set. A) MycN, cMyc and CIP2A show substantial 
expression levels in neuroblastoma with CIP2A displaying the lowest range.  
B) CIP2A correlates with MycN in the complete data set in the MycN non-amplified 
tumors, C) and shows a strong negative correlation with cMyc. D) Kaplan-Meier curves 
show that both MycN and CIP2A correlate significantly with poor survival probability, 
whereas cMyc is associated with better survival. The data set may be too small to show 
statistical significance for cMyc. E) Expression of CIP2A and MycN correlate significantly 
according to INSS stage, and cMyc shows an inverse trend.  
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Supplemental Figure 5. Clinical neuroblastomas express low levels of Sox2; and 
MycN does not correlate with neural stem cell markers Sox2, Nestin or Mushashi2. 
As shown in A) KOCAK and B) SEQC498 data sets, vast majority of the clinical 
neuroblastoma samples express low levels of Sox2 (within the log2 range of 5 to 9), and 
Sox2 levels don’t correlate with MycN. C) Expression of the neural stem cell marker 
Nestin does not correlate with Sox2 in KOCAK or D) SEQC498 data sets. E) Expression 
of the neural stem cell marker Mushashi2 shows weak if any correlation with MycN in the 
complete data set that is lost in Stage 4 tumors in KOCAK and F) SEQC498 data sets.  	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Supplemental Information 
MATERIALS AND METHODS 
 
In situ hybridization 
Embryos were fixed with 4% paraformaldehyde, washed with PBS/0.1% Tween (PBT), 
dehydrated in MeOH, and stored at −20°C. The avian MycN, cMyc and CIP2A (KIAA1524) 
probes were made by using cEST697p20, cEST191o11 and cEST895e1 
(www.chick.manchester.ac.uk), respectively, and the Sox10 and FoxD3 probes were made by 
cloning respective genes to DNA vectors from RT-PCR products made by using chicken whole 
embryo cDNA (HH7-12) as template. Whole-mount in situ hybridization was performed in 70oC 
as described (65, 66). Prior to hybridization, the later stage embryos (HH2-HH7) were bleached 
in 6% hydrogen peroxide for 1 h, permeabilized with 10 µg/ml proteinase K for 30 min. The 
embryos were imaged by using Zeiss Axioscope 2 and Zeiss ApoTome.2. Two-dimensional 
projections of the Z-stacks and contrast enhancement were performed with the Zen Blue 
software (Zeiss). 
 
Morpholino knockdown, expression constructs and HH4 electroporation of the chicken embryos 
FITC-conjugated morpholinos were purchased from Gene Tools LLC (www. gene-tools.com). 
The CIP2A (GAGACGCGGACGACATACCACATTC), and MycN 
(TCTTGCTGATCATTCCCGGCATGGC) translation blocking morpholinos were targeted to the 
respective 5’ UTR in close proximity of the ATG and a control morpholino was designed to 
assure lack of non-specific effects from electroporation 
(CTGCGATGAAAAACACGGGAGCACA). The MOs were diluted to a 1.5 mM concentration and 
electroporated together with an empty pGAG vector as carrier DNA (1 µg/ µl). The morpholino 
was injected as two-sided injections with control morpholino on the contralateral side (Fig S2A). 
The electroporation to target the ectoderm was carried out as previously described (67). Briefly, 
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the chicken embryos were collected on Whatman filter papers and electroporated at Hamburger 
and Hamilton (HH) stage 4 by using 5.3V and 5 pulses (50mA/100mA) and incubated on 
individual petri dishes (Falcon 1008 35x10mm) in thin albumin until they reached the desired 
stage. The coding sequence of human CIP2A was cloned into the pcDNA3.1 vector, and the 
chicken MycN was cloned into the PCI-RFP vector and injected in 3mg/ml concentration. To test 
the translation blocking ability of the morpholinos, 30bp of the 5’ UTR followed by the first 30bp 
of the coding sequence of the gene of interest (CIP2A or MycN) were cloned in front of the RFP 
gene in the PCI-RFP vector backbone that lacked the start codon. Co-electroporation of the 
construct with the respective morpholino efficiently blocked expression of RFP as compared to 
injection on the contralateral side with the control morpholino (Figs. S2B-D). 
 
Immunofluorescence and Western Blot  
For immunofluorescence, embryos were fixed with 4%PFA for 20 minutes, washed with PBT, 
blocked with 2.5% goat and 2.5% donkey serum o/n +4oC, and stained with the primary 
antibody in the block o/n +4oC, washed 5x with PBT and stained with the secondary antibody in 
block o/n +4oC. The embryos were then embedded in gelatin and sectioned at 12 µm. The 
sections were imaged by using fluorescence microscopy (Zeiss Axioscope 2 and Zeiss 
ApoTome.2). 
 
For Western Blot, the neuroblastoma cell line cells were grown in 6-well plates and lysed into 
200µl of the SDS lysis buffer (0,19M Tris-HCl, pH 6,8, 3 % SDS (20-%), 30% glyserol, 3 % β-
merkaptoethanol, 0,015 % bromphenol blue) after 2 days of RNAi infection and the WB protocol 
was carried out as previously described (37).  
 
Antibodies 
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The following antibodies were used for Western Blot: CIP2A (Santa Cruz sc-80659, 1:1000); 
MycN (Santa Cruz sc-791, 1:500); c-Myc (Abcam y69 1:1000); Sox2 (D6D9, Cell Signalling 
Technology, 1:500); GAPDH (5G4-6C5 Hytest ,1:200,000). For immunofluorescence: Pax7 and 
HNK-1 (3H5) from Developmental Studies Hybridoma Bank (1:10); Sox2 (Abcam 97959, 
1:2000), and and anti-Tyrosine Hydroxylase (Millipore Cat# AB152 RRID:AB_390204; 1:300). 
For PLA: MycN (rb) sc-791 and CIP2A (ms) made by The Edward K Chan laboratory at The 
University of Florida. The respective secondary antibodies were purchased from Alexa Fluor 
(1/1,000 dilution; http://www.bdbiosciences.com).  
 
Fluorescence quantification on the in vivo chicken embryo sections 
Fluorescent images of cross-sections of the embryos that were overexpressing MycN on one 
side of the embryo were quantified by using ImageJ. The Pax7 or Sox2 expression was 
normalized to expression of DAPI and the intensity of fluorescence of the mycN injected side 
was divided by the results on the control plasmid side. For the stage HH8 embryos, the 
quantified dorsal region was selected based on the area of Pax7 expression, whereas for the 
migrating neural crest cells stage HH12, an equally large area was manually selected from both 
sides of the embryo and levels of Pax7 from the MycN overexpressing side were compared with 
the control side. 
 
RNAi transfections 
Neuroblastoma cells were transfected at 30% confluence with 250 pmol of siRNA by using 
Oligofectamine (Invitrogen 12252011) according to manufacturer’s instructions. Three 
individual siRNAs were used for CIP2A together with a scrambled control (37, 68). 
 
In vitro culture of neuroblastoma cell lines 
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The SK-N-BE(2)  cells were cultured in F12 medium supplemented with 10% FCS, 1% 
pen/strep, 1% glutamine, and 1% NEAA, and the NGP cells were cultured in DMEM with 10% 
FBS and 1%pen/strep and 1% glutamine. Finally, the SK-N-AS cells were on grown in DMEM 
media with 10% FCS, 1% pen/strep, 1% glutamine, 1% NEAA on collagen-coated plates (0.05 
mg/mL).  
 
Proximity Ligation Assay (PLA) 
PLA was performed according to the manufacturer’s instructions for the Duolink kit (DUO92102, 
Sigma-Aldrich). Briefly, neuroblastoma cell lines were grown 80% confluent on coverslips in 12-
well plates, washed once with PBS and fixed in a mix of methanol /acetone (3:1) for 7 minutes. 
in -20oC. The fixed cells were washed 3x in PBS and the cells were blocked by placing the 
coverslips on 1 drop (always equals 25 µl) of blocking solution for 37 C for 30 minutes on the 
PLA dish. Primary antibodies were diluted in antibody diluent, and coverslips were placed on a 
drop of antibody solution o/N +4oC. The next day, the coverslips were washed 2 times for 5 
minutes on nutator at low speed in Buffer A followed by incubation in probe solutions for 1h at 
37oC (probes diluted 1:5 in antibody diluent), and washed 2 times for 5 minutes in buffer A. The 
ligation mix was diluted in H2O (1:5) and the ligase was diluted 1:40 in the mix, and the washed 
coverslip was placed on a drop of the mix for 30 minutes in 37oC followed by two washes in 
buffer A. For the light sensitive reaction, the amplification stock was diluted in H2O (1:5) and the 
polymerase was diluted in the amplification mix (1:80), and the coverslip was placed on a drop 
of the mix for 100 minutes at 37oC. Finally, the samples were washed twice in buffer B for 10 
minutes followed by one wash with 0.01X buffer B for 1minute, and the coverslips were let dry at 
room temperature in the dark for 20 minutes. Finally, the coverslips were mounted with 8µl of 
Duolink DAPI mounting media, let dry in the dark for 15 minutes and stored in -20oC. 
 
WST-1 viability assay 
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To measure cell viability and proliferation we used the WST-1 kit (Roche 5015944001) 
according to manufacturer’s instructions. Briefly, the cells were plated in 96 well plates (5-10 
000 cells per well) after 1-2 days of siRNA transfection and the cells were let grow until 70-80% 
confluent (2-4 days). Absorbance of the formazan dye was measured at 450nm. 
 
Soft agar assay 
To measure anchorage independent growth, the cells (5000 cells /well) were seeded in 12-well 
plates in their respective media mixed with agar (1ml media in 1.2% agar in the bottom, 1.5ml 
media in 0.4% agar on top and additional 1ml of media on top of the solidified agar) 1-2 days 
after siRNA transfection. The wells were incubated in 37oC for 10-14 days until colonies were 
formed. The crystal violet staining and imaging was performed as previously described (37). 
 
Statistical analyses for clinical neuroblastoma samples 
Three publically available data sets consisting of 649, 498 and 88 neuroblastomas (KOCAK, 
SEQC498 and Versteeg88, respectively) were acquired from R2: microarray analysis and 
visualization platform (http://r2.amc.nl), and used to analyze individual gene expression, gene 
correlations and survival. 
 
